Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1967 1
1970 1
1975 1
1977 1
1978 1
1979 4
1980 2
1981 1
1982 4
1983 3
1984 6
1985 8
1986 4
1987 4
1988 2
1989 6
1990 8
1991 7
1992 6
1993 9
1994 7
1995 6
1996 3
1997 7
1998 5
1999 7
2000 9
2001 8
2002 7
2003 7
2004 8
2005 3
2006 5
2007 5
2008 3
2009 4
2011 1
2012 4
2013 3
2014 12
2015 2
2016 3
2017 1
2019 4
2021 1
2022 2
2023 1
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Sealant success.
Feigal RJ. Feigal RJ. J Am Dent Assoc. 1999 Jul;130(7):926. doi: 10.14219/jada.archive.1999.0324. J Am Dent Assoc. 1999. PMID: 10438249 No abstract available.
FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
Feigal D. Feigal D. AIDS Treat News. 1997 Jun 20;(No 273):1-5. AIDS Treat News. 1997. PMID: 11364399
Rather than waiting for a major disease event to occur, the new kind of trial would record effective viral suppression over a period of time. Dr. David Feigal of the FDA's Division of Antiviral Drug Products discusses the problems that the proposed changes should solve, th …
Rather than waiting for a major disease event to occur, the new kind of trial would record effective viral suppression over a period of time …
Protease inhibitors and beyond: interview with David Feigal, M.D. Interview by John S James.
Feigal D. Feigal D. AIDS Treat News. 1995 Mar 24;(no 219):1-6. AIDS Treat News. 1995. PMID: 11362331
Dr. David Feigal, M.D., Director of the Division of Antiviral Drug Products of the U.S. Food and Drug Administration (FDA), agrees that protease inhibitors are the most promising single approach to HIV treatment today. ...The lottery method, used with Betaseron for multipl …
Dr. David Feigal, M.D., Director of the Division of Antiviral Drug Products of the U.S. Food and Drug Administration (FDA), agrees th …
The use of pit and fissure sealants.
Feigal RJ, Donly KJ. Feigal RJ, et al. Pediatr Dent. 2006 Mar-Apr;28(2):143-50; discussion 192-8. Pediatr Dent. 2006. PMID: 16708789 Review.
The proceedings of the California Stem Cell Agency.
Feigal EG, DeWitt ND. Feigal EG, et al. Stem Cells Transl Med. 2014 Jun;3(6):671-2. doi: 10.5966/sctm.2014-0068. Epub 2014 Apr 25. Stem Cells Transl Med. 2014. PMID: 24771394 Free PMC article.
Evaluation of a school-based pit and fissure sealant programme in Iranian children.
Memarpour M, Shafiei F, Shokouh P, Shaddel M. Memarpour M, et al. Oral Health Prev Dent. 2011;9(4):381-6. Oral Health Prev Dent. 2011. PMID: 22238737
MATERIALS AND METHODS: A total of 420 sealed first permanent molar teeth in 179 students (mean age 8 years, 6 months) were evaluated for fissure sealant retention, occlusal caries status and Feigal criteria. All teeth were examined 1.5 years after application. The fissure …
MATERIALS AND METHODS: A total of 420 sealed first permanent molar teeth in 179 students (mean age 8 years, 6 months) were evaluated for fis …
Task force 2: Investigator participation in clinical research.
Califf RM, Nissen SE, DeMaria AN, Ohman EM, Pitt B, Willerson JT, Bilheimer DW, Cohn JN, Feigal DW Jr, Hampson L, Lorell BH, Pepine CJ, Popp RL. Califf RM, et al. J Am Coll Cardiol. 2004 Oct 19;44(8):1729-36. doi: 10.1016/j.jacc.2004.08.039. J Am Coll Cardiol. 2004. PMID: 15489116 Free article. Review. No abstract available.
Medical device development: from prototype to regulatory approval.
Kaplan AV, Baim DS, Smith JJ, Feigal DA, Simons M, Jefferys D, Fogarty TJ, Kuntz RE, Leon MB. Kaplan AV, et al. Circulation. 2004 Jun 29;109(25):3068-72. doi: 10.1161/01.CIR.0000134695.65733.64. Circulation. 2004. PMID: 15226221 Review. No abstract available.
211 results